Neuroblastoma survivors are at elevated risk for psychological impairment.
Researchers achieved a 3-year event-free survival rate of 73.2% for tandem transplant patients.
The FDA fast-tracked the new drug for its safety and effectiveness in the treatment of a rare pediatric disorder.
Neurology Advisor Articles
- Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- FDA Approves Powerful New Opioid Despite Criticisms
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Efficacy of Naftazone on Motor Symptoms of Parkinson Disease
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- Pediatric Migraine: Evidence-Based Alternative Management
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Circadian, Circaseptan Rhythms Prevalent in Epileptic Seizure Cycles
- Jolt Accentuation of Headache Not a Universal Indicator of Acute Meningitis
- Reduced Survival for Patients With Idiopathic Parkinsonism
- ACA Implementation Decreased Rates of Therapy Nonadherence in Stroke Survivors
- Fluorescence Can ID High-Grade Glioma During Sx for Brain Tumor